<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>FDA批准Alzheimer的药物，尽管它是否有效地辩论 FDA Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">FDA Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works<br/>FDA批准Alzheimer的药物，尽管它是否有效地辩论 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-08 03:15:49</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/22e5d2729d602a44e4e8d1d7e2567adc.jpg"><img src="http://img2.diglog.com/img/2021/6/22e5d2729d602a44e4e8d1d7e2567adc.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>The Food and Drug Administration on Monday  approved the first new medication for Alzheimer’s disease in nearly two decades,  a contentious decision, made despite opposition from the agency’s independent advisory committee and some Alzheimer’s experts who said there was not enough evidence that the drug can help patients.</p><p>周一的食品和药物管理局在近二十年内批准了阿尔茨海默病的第一种新药，尽管原子能机构的独立咨询委员会和一些阿尔茨海默氏症的专家们表示，但有一些证据表明药物可以帮助患者的证据。</p><p> The drug, aducanumab, which will go by the brand name Aduhelm, is a monthly intravenous infusion intended to slow cognitive decline in people with mild memory and thinking problems. It is the first approved treatment to attack the disease process of Alzheimer’s instead of just addressing dementia symptoms.</p><p> 将通过品牌名称Aduhelm进行的药物，Aducanumab，是每月静脉注射，旨在缓慢记忆力和思维问题的人们的认知衰退。它是第一次批准攻击阿尔茨海默氏病的疾病过程的批准治疗，而不是仅解决痴呆症状。</p><p> Recognizing that clinical trials of the drug had provided incomplete evidence to demonstrate effectiveness, the F.D.A. granted approval on the condition that the manufacturer, Biogen, conduct a new clinical trial.</p><p> 认识到该药物的临床试验提供了不完整的证据来证明有效性，F.D.A.批准批准制造商，生物原性进行新的临床试验。</p><p> During the several years it could take for that trial to be concluded, the drug will be available to patients, the agency said. If the post-market study, called a Phase 4 trial, fails to show the drug is effective, the F.D.A. can — but is not required to — rescind its approval.</p><p> 在多年来，该审判的结论可能需要，该药物将在患者提供，该机构表示。如果市场后的研究，称为4阶段试验，未能显示药物是有效的，F.D.A.可以 - 但不需要 - 撤销其批准。</p><p> “The data included in the applicant’s submission were highly complex and left residual uncertainties regarding clinical benefit,” the F.D.A.’s director of the Center for Drug Evaluation and Research, Dr. Patrizia Cavazzoni, wrote on the agency’s website.</p><p> “申请人提交中所包含的数据是对临床福利的高度复杂和留下的剩余不确定性，”F.D.A.毒药研究中心董事，Patrizia Cavazzoni博士在该机构的网站上写道。</p><p> But, she said, the agency had decided to approve the drug through a program called  accelerated approval, which is designed “to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit.”</p><p> 但是，她说，原子能机构已决定通过呼吁加速批准的计划批准该药物，该计划被设计为“为患有未满足需求的严重疾病的患者提供潜在有价值的疗法，并且存在期望临床利益尽管有一些剩余的不确定性。“</p><p> Michel Vounatsos, Biogen’s chief executive, called the approval a “historic moment.” He said in a statement that the company believes the drug “will transform the treatment of people living with Alzheimer’s disease and spark continuous innovation in the years to come.”</p><p> Biogen队长的Michel Vountsos，称批准了“历史性时刻”。他在一份声明中表示，该公司认为该药物“将改变与阿尔茨海默病的待遇，并在未来几年引发持续创新。” </p><p> Biogen, is expected to reap billions of dollars from the drug. Shortly after the F.D.A.’s approval,  the company announced that the list price would be $56,000 a year, based on an average patient’s weight. Beyond that, there will most likely be tens of thousands of dollars in costs for diagnostic testing and brain imaging.</p><p>Biogen，预计将从药物中获得数十亿美元。在F.D.A.批准之后不久，该公司宣布，每年的清单价格为56,000美元，基于平均患者的体重。除此之外，诊断检测和脑成像的成本很可能很可能是数万美元。</p><p> Because Alzheimer’s primarily affects older people, most costs are expected to fall to Medicare’s Part B program. Medicare has not yet said how it would cover the drug and its associated costs.  The insurer Cigna projects that beyond the cost of the medicine, diagnostic and safety monitoring expenses will total about $30,000 per patient in the first year of treatment, plus about half that each subsequent year.  It, too, has not yet determined how it will cover the drug.</p><p> 由于阿尔茨海默氏症主要影响老年人，预计大多数成本将落到Medicare的B部分计划。 Medicare尚未表示如何涵盖药物及其相关成本。保险公司的Cigna项目超出了药物，诊断和安全监测费用的成本，每位患者在治疗的第一年总计约为30,000美元，加上大约一半的一年。它也尚未确定它如何覆盖药物。</p><p> Patient advocacy groups had lobbied vigorously for approval because there are so few treatments available for the debilitating condition and other drugs in clinical trials, while more promising, are most likely three or four years away from potential approval.</p><p> 患者倡导团体大会促进批准，因为有很少的治疗方法可用于衰弱的病症和临床试验中的其他药物，而有希望的是最有可能的三到四年的潜在批准。</p><p> But the  F.D.A. advisory committee, along with an  independent think tank and  several prominent experts — including some Alzheimer’s doctors who worked on the aducanumab clinical trials — said the evidence raised significant doubts about whether the drug is effective. They also said that even if aducanumab could slow cognitive decline in some patients, the benefit suggested by the evidence would be so slight that it would not outweigh the risk of swelling or bleeding in the brain that the drug caused in the trials.</p><p> 但是f.d.a.咨询委员会以及一个独立的智库和几位着名专家 - 包括一些在阿卡曼姆临床试验上工作的阿尔茨海默氏症的医生 - 表示，证据提出了对药物是否有效的显着疑虑。他们还表示，即使达松妥替纳布在某些患者的认知下降缓慢，证据表明的好处也会如此轻微，即它不会超过在试验中造成的药物肿胀或出血的风险。</p><p> About  six million people in the United States and roughly  30 million globally have Alzheimer’s, a number expected to double by 2050. Currently,  five medications approved in the United States can delay cognitive decline for several months in various Alzheimer’s stages.</p><p> 在美国约有600万人和大约3000万人拥有Alzheimer，一个人预计到2050年，美国批准的五种药物可以在各种Alzheimer的阶段推迟认知下降数月。</p><p> Although the clinical trials for aducanumab were conducted on specific populations of patients — those with mild cognitive impairment or early-stage Alzheimer’s whose brains contained high-than-normal levels of amyloid — the  F.D.A.’s label for the drug does not contain any such restrictions. The label simply says the drug is “for the treatment of Alzheimer’s disease.”</p><p> 虽然对患者的特定群体进行了患者的临床试验 - 具有轻度认知障碍或早期阿尔茨海默氏症的患者含有高于正常的淀粉样蛋白水平 -  FDA的药物标签不含任何此类限制。标签简而言之表示药物是“用于治疗阿尔茨海默病”。</p><p> The label says that patients should have a brain MRI within the year before starting the drug and should obtain additional MRIs before the seventh and twelfth monthly doses. The label says the “most common adverse reactions” include brain swelling, headache, brain microbleeds and falls.</p><p> 该标签表明，患者在开始药物前的一年内应有脑MRI，并在第七和第十二个剂量之前获得额外的MRI。标签表示“最常见的不良反应”包括脑肿胀，头痛，脑微微斑纹和跌倒。 </p><p> Infusions will take about an hour and should start at a low dose, which should increase every two months until it reaches the high dose of 10 mg/kg.</p><p>输注需要大约一个小时，应以低剂量开始，这应该每两个月增加一次，直到它达到10mg / kg的高剂量。</p><p> In 2012, the F.D.A.  revoked its approval of the drug Avastin as a breast cancer treatment after additional studies did not show enough benefit. But some other cancer drugs have  retained approval even though additional trials failed to confirm the drugs were beneficial. The agency has also been criticized in the past for failing to make sure the follow-up studies are done.</p><p> 2012年，F.D.A.在额外研究后，撤销药物Avastin的批准作为乳腺癌治疗并未显示出足够的益处。但其他一些癌症药物即使额外的试验未能确认药物是有益的，也要保留批准。原子能机构在过去批评，因为未能确保完成后续研究。</p><p> Alzheimer’s trials are already challenging to conduct because it is often difficult to recruit enough participants. Because the condition can progress very gradually, trials need to be large and continue for many months in order to be able to see if a drug is slowing cognitive decline.</p><p> 阿尔茨海默氏症的试验已经挑战行为，因为它往往难以招募足够的参与者。因为条件可以非常逐步进展，因此试验需要大而持续数月，以便能够看到一种药物是否正在减缓认知下降。</p><p> Several experts expressed skepticism that Biogen would be able to recruit many participants in the United States for a post-market trial because patients who can get a drug from their doctors are often reluctant to take the chance of receiving a placebo in a clinical trial.</p><p> 一些专家表示，生物原性能够在市场后审判中招募许多参与者，因为可以从医生那里获得药物的患者往往不愿意在临床试验中接受安慰剂的机会。</p><p>  “Once the product is approved, the cat’s out of the bag, the horse is out of the barn,” said Dr. G. Caleb Alexander, a member of the F.D.A. advisory committee, who is an internist, epidemiologist and expert on drug safety and effectiveness at the Johns Hopkins Bloomberg School of Public Health. “There’s no way to recover the opportunity to understand whether or not the product really works in the post-approval setting.”</p><p>  “一旦该产品获得批准，猫从袋子里出来，马就是谷仓，”F.D.A的成员G. Caleb Alexander博士说。咨询委员会是一个内部，流行病学家和药物安全和有效性专家，在约翰霍金斯彭博公共卫生学院。 “没有办法恢复机会了解产品是否在批准后的环境中真正有效。”</p><p> Companies can conduct post-market trials with participants from other countries, but may face similar challenges recruiting participants if those countries approve the drug before trials are completed. Aducanumab has not yet been approved outside of the United States, but Biogen has filed for regulatory review in the European Union, Japan, Brazil and elsewhere.</p><p> 公司可以与其他国家的参与者进行市场后试验，但如果这些国家在审判完成前批准该药物，则可能面临着招聘参与者的挑战。阿杜纳姆尚未在美国以外尚未批准，但Biogen已在欧盟，日本，巴西和其他地方提出监管审查。</p><p> Aducanumab, a monoclonal antibody, targets a protein, amyloid, that clumps into plaques in the brains of Alzheimer’s patients and is considered a biomarker of the disease. One thing both critics and supporters of approval agree on is that the drug substantially reduces levels of amyloid, and the F.D.A. said that the drug’s effect on a biomarker qualified it for the accelerated approval program.</p><p> Aducanumab，一种单克隆抗体，靶向蛋白质，淀粉样蛋白，在阿尔茨海默氏症患者的大脑中丛将其丛成斑块，并被认为是疾病的生物标志物。批评和批准支持者的一件事达成一致认为，该药物显着降低了淀粉样蛋白水平，以及F.D.A.他说，药物对生物标志物的影响有资格获得加速批准计划。 </p><p> Still, reducing amyloid is not the same thing as slowing symptoms of dementia. Over more than two decades of clinical trials, many amyloid-reducing drugs failed to address symptoms, a history that, some experts say, made it especially important that aducanumab’s data be convincing.</p><p>尽管如此，还原淀粉样品与减缓痴呆症状的症状不同。超过二十多年的临床试验，许多淀粉样量减少药物未能解决症状，一些专家所说的历史，使得Aducanumab的数据令人信服尤为重要。</p><p> “Although the Aduhelm data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that Aduhelm reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients,” Dr. Cavazzoni, of the F.D.A., wrote on the agency’s site.</p><p> “虽然ADUHELM数据对其临床效益很复杂，但FDA已经确定存在大量证据表明Aduhelm在大脑中降低淀粉样蛋白β斑块，并且这些斑块的减少合理可能预测患者的重要益处，”博士。FDA的Cavazzoni在原子能机构的网站上写道。</p><p> Biogen officials said that the drug provided long-awaited support for a theory that attacking amyloid can help if done early enough. Supporters of approval also said that it’s possible that clearing amyloid early on could help rein in the disease down the road, providing additional benefit beyond slightly delayed early decline. But Alzheimer’s experts note that supposition is completely untested.</p><p> 生物原生官员表示，该药物提供了期待已久的支持，这是一个攻击淀粉样蛋白可以帮助的理论，如果足够早熟。批准的支持者还表示，早期可能会清除淀粉样蛋白可以帮助抑制在道路上的疾病中，提供额外的益处，超出略微延迟的早期下降。但阿尔茨海默氏师的专家们注意，假设是完全未经测试的。</p><p> The crux of the controversy over aducanumab involved two Phase 3 trials with results that contradicted each other: One suggested the drug slightly slowed cognitive decline while the other trial showed no benefit. The trials were stopped early by a data monitoring committee that found aducanumab didn’t appear to be showing any benefit. Consequently, over a third of the 3,285 participants in those trials were never able to complete them.</p><p> 争议的争论涉及两期3阶段的试验，结果彼此相矛盾：人们提出了这种药物略微放缓的认知下降，而其他试验没有任何益处。通过数据监测委员会提前停止了试验，发现阿杜纳姆似乎没有表现出任何益处。因此，这些试验中的3,285名参与者中的三分之一从未完成过它们。</p><p> Biogen later said that it had analyzed additional data and concluded that in one of the trials a high dose of aducanumab could delay cognitive decline by 22 percent or about four months over 18 months. In the trial’s primary measurement, the high dose appeared to slow decline by 0.39 on an 18-point  scale rating memory, problem-solving skills and function. A lower dose in that trial and high and low doses in the other showed no statistically significant benefit over a placebo.</p><p> 生物原说，它已经说它分析了额外的数据并得出结论，在其中一项试验中，高剂量的阿杜曼巴可延迟认知下降22％或约4个月超过18个月。在试验的主要测量中，高剂量似乎在18分尺寸评级内存，解决方案技能和功能上会减少0.39。在该试验和高剂量中的较低剂量显示在安慰剂上没有统计学显着的益处。</p><p> “There’s so little evidence for effectiveness,” said Dr. Lon Schneider, director of the California Alzheimer’s Disease Center at the University of Southern California and one of many site investigators who helped conduct one of the aducanumab trials. He added, “I don’t know what caught the F.D.A.’s fancy here.”</p><p> “有效的证据表明，南加州大学加州阿尔茨海默氏病中心主任Lon Schneider博士说，众多网站调查人员之一，他们帮助进行了一项抵押植物试验。他补充说：“我不知道是什么抓住了f.d.a.的花哨。”</p><p> At the time of the advisory committee meeting, in November 2020, there was not unanimity within the F.D.A. itself. An F.D.A. clinical analyst said there was a sufficient case for approval, but an F.D.A. statistician wrote that another trial was needed because “there is no compelling, substantial evidence of treatment effect or disease slowing.”</p><p> 在咨询委员会会议的时候，在2020年11月，在F.D.A中没有一致。本身。一个f.d.a.临床分析师表示，有足够的案件批准，但是一个F.D.A.统计名称写道，需要另一项试验，因为“没有引人注目的，治疗效果或疾病放缓的实质性证据。” </p><p> After the  advisory committee’s blistering rejection, the F.D.A. extended its decision deadline by three months and sought additional information from Biogen, which hasn’t said what it submitted.</p><p>在咨询委员会的后果拒绝之后，F.D.A.将其决定截止日期扩大了三个月，并寻求Biogen的其他信息，并没有说它提交的内容。</p><p> Biogen and some researchers who favored approval of the drug said that given the need for Alzheimer’s medications, the single positive trial, plus results from a small safety trial and aducanumab’s ability to reduce amyloid justified making it available to patients now.</p><p> 生物原和一些有利于该药物批准的研究人员表示，鉴于需要阿尔茨海默治疗的药物，单一阳性试验，从小型安全试验和达uCanumab减少淀粉样证的能力，使其能够为患者提供给患者。</p><p> Dr. Stephen Salloway, who has received research and consulting fees from Biogen but wasn’t paid for being an aducanumab trial site principal investigator, said that while he understood the concerns about the data, “the totality of the evidence favors approval, and F.D.A. approval will open the door to a new treatment era for Alzheimer’s disease that we can build on.”</p><p> Stephen Salloway博士获得了生物原性的研究和咨询费用，但由于成为Aducanumab试验网站主要调查员而不是支付的，但虽然他了解对数据的担忧，“证据批准的总体批准，以及F.D.A。批准将对我们可以建立的阿尔茨海默病的新待遇时代打开大门。“</p><p>  The F.D.A. typically follows advisory committee recommendations and usually requires two convincing studies for approval, but it has made exceptions, especially for severe diseases that lack treatments. But some experts worry that aducanumab’s approval could lower standards for future drugs, allowing them onto the market before experts in the field are convinced the benefits outweigh any safety risks.</p><p>  f.d.a.通常遵循咨询委员会的建议，通常需要两个令人信服的审批研究，但它已成为异常，特别是对于缺乏治疗的严重疾病。但有些专家担心阿杜纳姆采购批准可能会降低未来药物的标准，允许他们在该领域专家处于相信的福利方面的福利，超过任何安全风险。</p><p> The risks with aducanumab involve brain swelling or bleeding experienced by  about 40 percent of Phase 3 trial participants receiving the high dose. Most were either asymptomatic or had headaches, dizziness or nausea. But such effects prompted  6 percent of high-dose recipients to discontinue. No Phase 3 participants died from the effects, but one safety trial participant did.</p><p> 含有Aducanumab的风险涉及脑肿胀或出血所经历的约40％的第3期试验参与者接受高剂量。大多数是无症状或头痛，头晕或恶心。但这种影响促使6％的高剂量接受者停止。没有第3阶段参与者从效果中死亡，但一个安全试验参与者确实如此。</p><p> Similar side effects have occurred in trials of previous amyloid-lowering drugs, but doctors consider them manageable if a patient is evaluated regularly with brain scans. Still, even supporters of approval said that conducting such safety monitoring was more difficult when not done in the carefully controlled regimen of a study.</p><p> 在先前淀粉样淀粉样蛋白降低药物的试验中发生了类似的副作用，但如果经常用脑扫描定期评估患者，医生认为它们是可管理的。尽管如此，即使是批准的支持者也表示，在学习的精心控制的方案中没有完成，更加困难。</p><p> “It’s going to be challenging when it’s applied more broadly, outside of a clinical trial,” said Dr. Salloway, director of neurology and the Memory and Aging Program at Butler Hospital in Providence, R.I.</p><p> “在临床审判之外更广泛地应用，普罗维登斯（Providence）普罗维登斯普罗夫特医院的记忆和老化计划总监博士说，这将具有挑战性。 </p><p> Biogen is  expecting to launch the drug quickly, with more than 600 sites across the country expected to administer it. Clinics for patients with cognitive problems have been scrambling to prepare.</p><p>生物原期预计将迅速推出该药物，预计全国各地的600多个网站将会管理。认知问题患者的诊所已经争先恐后地准备。</p><p> Dr. Jeffrey Burns, director of the University of Kansas Health System’s memory clinic and a site investigator for one trial, said he expected “the phone to be ringing off the hook.” He estimates 25 to 40 percent of the clinic’s roughly 3,000 patients might be eligible, but it doesn’t have enough neurologists.</p><p> 堪萨斯州卫生系统大学的记忆诊所和一个试验的网站调查员Jeffrey Burns博士说，他预计“手机响起。”他估计25％至40％的诊所大约3,000名患者可能有资格，但它没有足够的神经科学家。</p><p> Several Alzheimer’s doctors who believe the case for approving aducanumab is too weak said they would now feel ethically compelled to make it available. They believe that many patients, even when told of the problematic evidence, would try the drug because they would assume there was a compelling reason it received F.D.A. approval.</p><p> 几个阿尔茨海默氏症的医生认为批准的伊索曼巴布的案例太弱了，说他们现在觉得越来越强迫它可以实现它。他们相信，许多患者，即使是在讲述问题的证据时，也会试图这种药物，因为他们会认为它收到了令人信服的原因。赞同。</p><p> “I had this conversation with a real patient who was very interested in it,” said Dr. David Knopman, a clinical neurologist at the Mayo Clinic and a site principal investigator for one trial who co-wrote  an article saying the evidence was insufficient to show benefit. “I presented the data to the patient and her husband, and they didn’t hear a word I said about my concerns. All they heard was there might be benefit.”</p><p> “我与一个非常感兴趣的真正患者对其进行了这种谈话，”梅奥诊所的临床神经科医生David Knopman博士和一名审判的网站主要调查员说，他们共同编写了一篇文章，说证明证据不足显示福利。 “我向患者和丈夫提出了数据，他们没有听到我对我的担忧的一句话。他们听到的只是有可能受益。“ </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.nytimes.com/2021/06/07/health/fda-approves-alzheimers-drug.html">https://www.nytimes.com/2021/06/07/health/fda-approves-alzheimers-drug.html</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/批准/">#批准</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/approves/">#approves</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/药物/">#药物</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>